Floatz logo

BMS 986156

Metastatic Malignant Neoplasm in the Thoracic Cavity

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Metastatic Malignant Neoplasm in the Thoracic Cavity cohort.

Asset / SponsorPhaseRating
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Docetaxel
Phase 3B
HYPERICUM
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 1/2CCC
Catequentinib
JIANYANG WANG
Phase 2CCC

View all 23 →

Same molecule, other indications

BMS 986156 is also rated in:

metastatic carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
52 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →